FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

vtgn20220331_10k.htm

FDA fast-tracking approval of new drugs — fewer trials, less info

SEC Filing Vistagen Therapeutics, Inc

Pharmaceutical payments to psychiatrists and betrayal of the

FDA rushes approval of dementia drug that quadruples risk of death

FDA Law Blog

FDA fast-tracking approval of new drugs — fewer trials, less info

FDA's Fast-Track for Rexulti Raises Concerns

Pharm Exec's Emerging Pharma Leaders 2016

FDA approves world's first vaccine for 'emerging global health

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

SEC Filing Vistagen Therapeutics, Inc

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks